BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Blogs » BioWorld MedTech Perspectives » FDA user fees: A necessary evil?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / FDA

FDA user fees: A necessary evil?

March 9, 2012
By Mark McCarty

The FDA medical device review mechanism has come under fire from many quarters for some time now, but one of the criticisms of the 510(k) and PMA programs is that the reviews are funded by user fees, a claim that can be made of pharmaceuticals, biotech and now even FDA’s overview of food production. Opponents can complain all they want about user fees, but what can they do about them?

As has been widely reported, the Obama administration has proposed that FDA’s total budget for FY 2013 would rise by double-digit percentages, but 98% of that increase comes from user fees. Call me a cynic, but I have a tough time believing that Congress will be able to keep its hands off that last 2% – or more – of appropriated monies in an effort to get a handle on the amazingly large U.S. federal budget deficit. That’s an understandable move in the current climate, but past congresses and presidents don’t have that fig leaf to explain their lassitude where the FDA budget is concerned.

So opponents of user fees currently face a fairly immovable budgetary object, but it won’t always be that way (we hope). This raises the question, however, of why the expression of these adversarial views has had no effect. After all, it's not just outside groups who don’t like user fees. Industry doesn’t rant about them but device makers can’t be fond of them, especially the smaller firms with limited financial resources.

One way of looking at this is that nothing gets the attention of the folks on Capitol Hill like a call from a constituent. And nothing lights a fire under their behinds faster than multiple calls from constituents on a particular matter. Would that work for user fees?

I’m not claiming that outrage from the heartland would necessarily put an end to user fees, but it’s tough to see how they could be eliminated without such an outcry. And the thing I find most conspicuous about this discussion is how it always involves the same message delivered by the same faces living in the same zip codes. The conversation is all inside the Beltway.

Like it or not, Congress won’t end user fees unless someone tries to get the citizenry involved, but ask yourself this: When was the last time you heard someone with the necessary credibility (or bankroll) propose “taking it to the people”? The Alliance for a Stronger FDA is probably the best hope for such an undertaking, but I doubt seriously its member organizations are prepared to fork over the cash needed for such an effort, and the Alliance might not be interested in fighting that fight in the first place.

Ergo, we can only conclude that the effort will not be undertaken, and therefore FDA user fees are the necessary evil with which we must all live. So get over it already.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing